Company intelligence / Profile preview

Eirion Therapeutics

Woburn, Massachusetts, United Stateseirionthera.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Eirion Therapeutics develops next-generation prescription products for aesthetic medicine and medical dermatology. Its clinical-stage pipeline includes treatments targeting wrinkles, excessive sweating, androgenic alopecia, and hair greying. The company has reported promising early results with novel topical agents for androgenic alopecia as of January 2025. Lead assets include a botulinum toxin A product in Phase 2 trials for hyperhidrosis and small molecule/topical drugs in earlier stages.

Therapeutic areas: Dermatology
Modalities: Toxin (e.g., Botulinum toxin A)Small molecule drugUniversal CAR-T (listed in pipeline data but not detailed elsewhere)
Industry: Biotech

Drug pipeline

5 assets

AI-09

4 more assets in the full pipeline.

Partnerships

Haohai Biological Technology (investor/partner)

Beyond the preview

Go deeper on Eirion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eirion Therapeutics.